v3.25.2
Segment Reporting
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

12. Segment Reporting

Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment related to the development of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The Company’s Chief Executive Officer (CEO) serves as the CODM.

The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company’s consolidated net loss. Through this analysis, the CEO assesses performance by comparing budget to actual results, and then decides how to allocate resources to invest in the Company’s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.

The table below is a summary of the segment loss, including significant segment expenses (in thousands):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Program expenses

 

 

 

 

 

 

 

 

 

 

 

 

 Navacaprant (NMRA-140) program

 

$

(22,257

)

 

$

(25,552

)

 

$

(46,750

)

 

$

(49,871

)

 M4 PAM programs

 

 

(2,370

)

 

 

(1,278

)

 

 

(5,252

)

 

 

(4,802

)

 NMRA-511 program

 

 

(2,257

)

 

 

(1,810

)

 

 

(4,837

)

 

 

(3,697

)

 Preclinical programs

 

 

(1,459

)

 

 

(1,422

)

 

 

(2,461

)

 

 

(3,831

)

Research and development personnel-related costs

 

 

(7,617

)

 

 

(15,368

)

 

 

(19,943

)

 

 

(26,243

)

General and administrative expense

 

 

(15,316

)

 

 

(15,194

)

 

 

(34,101

)

 

 

(29,511

)

Interest income, net

 

 

1,814

 

 

 

5,271

 

 

 

4,888

 

 

 

11,636

 

Other segment items(1)

 

 

(3,269

)

 

 

(3,347

)

 

 

(12,267

)

 

 

(6,102

)

 Net loss

 

$

(52,731

)

 

$

(58,700

)

 

$

(120,723

)

 

$

(112,421

)

(1) Includes other research and development costs, provision for income taxes, and other income (expense).